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Background
In 2008, we stated that ‘the die was cast’ regarding the emergence 
and nationwide spread of extensively resistant (XDR) and pan-
drug-resistant (PDR) Gram-negative fermentative bacteria such 
as Escherichia coli and Klebsiella pneumoniae.1 This prediction 
was based on the fact that suboptimal antibiotic management as a 
whole (excessive duration, use of multiple often inappropriate or 
unnecessary agents, and a virtual absence of de-escalation) was rife 
in clinical practice in most institutions, and that prescribers ignored 
antibiotic ‘stewardship’ as a means of combating the emergence of 
XDR and PDR Gram-negative bacilli (GNB). 
Subsequently, carbapenem-resistant Enterobacteriaceae (CRE) 
have indeed become our ‘worst nightmare’, locally and internationally, 
and pose a major threat to the viability of all currently available 
antibiotics.2-4 These GNB are resistant to all standard antimicrobial 
agents and salvage therapy with tigecycline, colistin and/or fosfomycin 
has become the last resort in life-threatening infections. Numerous 
outbreaks and epidemics with these organisms have been reported, 
they have become endemic in several institutions, and increased 
mortality has been ascribed to them.2-4 The imminent threat of 
untreatable infections is highlighted by the recent emergence, and 
inter-hospital spread in Greece, of CRE resistant even to colistin.5,6 
Carbapenemases
Carbapenem resistance among Enterobacteriaceae can be conferred 
by several genetic mechanisms, but epidemiologically the most 
important of them results in the production of beta-lactamases 
(carbapenemases), which hydrolyse carbapenems and most other 
beta-lactams. These genes mostly reside on large plasmids which 
frequently contain other resistance determinants, such as those that 
confer resistance to the aminoglycosides and reduced susceptibility 
to the fluoroquinolones. 
The carbapenemases belong to different classes and include:
•	 K. pneumoniae carbapenemases (KPCs) and Guiana extended-
spectrum β-lactamases (GESs) (class A) 
•	 the metallo-β-lactamases (MBLs), such as the Verona integron-
encoded MBLs (VIMs) and the recently described New Delhi 
metallo-β-lactamases (NDM-1) (class B)
•	 oxacillinase-type carbapenemases such as OXA-48 and its 
derivates, which also occur in Enterobacteriaceae (class D).
Since 1 March 2010 the Molecular Biology Laboratory at 
the Ampath National Reference Laboratory has been screening 
Enterobacteriaceae for the presence of these novel genes, 
and recently the emergence of NDM-1 for the first time in 
South Africa, and KPC-2 for the first time in Africa, was 
documented among clinical isolates of K. pneumoniae and 
Enterobacter cloacae in hospitalised patients in Johannesburg 
and Pretoria, respectively.4 As depicted in Fig. 1, the emergence 
of the broad-spectrum antibiotic-inactivating enzyme, OXA-48, 
and its derivatives among Enterobacteriaceae from hospitalised 
patients in Johannesburg, Cape Town and Port Elizabeth has been 
confirmed (unpublished, J Coetzee, February 2012). Furthermore, 
VIMs have been detected in K. pneumoniae in Johannesburg 
and GESs in Enterobacteriaceae in hospitals in Cape Town (K. 
pneumoniae), Bloemfontein (K. oxytoca), Witbank (E. cloacae) 
and Port Elizabeth (Serratia marcescens) (unpublished, J Coetzee, 
February 2012). 
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New, effective antibiotics are only likely to become available in 
15 - 20 years. To prevent deaths from untreatable Gram-negative 
infections in South Africa, the rights of any doctor, whether 
in general or in hospital practice, to indiscriminately prescribe 
whatever antibiotic they wish, and in whatever fashion, must be 
challenged. Furthermore, although prevention of the emergence 
and subsequent spread of carbapenem-resistant Enterobacteriaceae 
(CRE) has focused on acute and chronic care facilities and inter alia 
on antibiotic exposure in these institutions, CRE may soon become 
an issue within entire communities, highlighting a role for public 
health authorities in CRE prevention efforts.
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Risk factors for acquisition
Antibiotic exposure
Exposure to antibiotics is a prominent risk factor for CRE. Specific 
antibiotics and specific antibiotic classes have frequently been 
implicated as risk factors for colonisation or infection with CRE, and 
these include all the carbapenems, cephalosporins, fluoroquinolones, 
aminoglycosides and β-lactam/β-lactamase inhibitors.3 Studies have 
also shown that prior carbapenem therapy is not a prerequisite 
for carbapenem resistance among E. coli or K. pneumoniae.3,4 The 
plasmids that confer such resistance frequently carry additional 
resistance determinants that confer cross-resistance to most other 
antibiotic classes. Consequently, prior use of any antibiotic may select 
for a carbapenemase-producing GNB. 
Healthcare exposure
The major risk factors for acquiring KPCs (colonisation and/or 
infection) are similar to those for extended-spectrum β-lactamases 
(ESBLs), the prevalence of which is extremely high in South 
Africa. For example, the ESBL rate for K. pneumoniae cultured 
from complicated intra-abdominal infections in private hospitals 
is 41.2% and that for bacteraemic isolates in the public sector 
55 - 74%.7,8 
These risk factors include:3,9
•	 organ or stem cell transplantation
•	 intensive care unit admission
•	 poor functional status
•	 severe illness
•	 mechanical ventilation
•	 prolonged hospitalisation
•	 surgery.
Similar to ESBLs, it also appears that long-term care facilities 
are reservoirs of KPCs because they act as a point of convergence 
of patients at high risk, amplified by cross-transmission, and this 
facilitates regional dissemination.3,10 
Emerging evidence suggests that the presence of a high ‘invasive-
device score’ is also a predictor of CRE. For K. pneumoniae, the 
presence of a central venous line (odds ratio (OR) 5.22; 95% 
confidence interval (CI) 2.38 - 11.46; p<0.001) and a urinary catheter 
(OR 7.53; 95% CI 3.49 - 16.26; p<0.001) are significantly associated 
with acquisition of KPC.9 
Transfer of patients who have been hospitalised in medical 
facilities or countries where endemicity of CRE isolates has been 
established is also a major risk factor.
Prevention of CRE
Rapid routine molecular detection of CRE is essential to optimise 
therapy and improve outcomes, and to limit the spread of such 
resistance through aggressive infection control, including the screening 
of high-risk patients and the facilitation of ‘search and contain’ tactics.4 
Detection of carriers of CRE is currently by far the most important 
factor preventing further dissemination in hospital settings. 
Antibiotic utilisation
Delaying the emergence of carbapenem resistance, particularly 
in areas of South Africa where resistance is still uncommon, can 
decrease the impact of CRE. In this regard, antibiotic stewardship 
programmes (ASPs) are crucial to prevent the emergence of CRE. 
Because so few agents are available to treat the present population of 
XDR organisms, it is extremely difficult to study restrictive formulary 
interventions, and if they were employed they would be unlikely to 
be successful. Rather than targeting a specific class of antibiotics 
or limiting use of specific agents, an overall reduction in antibiotic 
burden is recommended as a focus for ASPs.3 
Cumulative antibiotic exposure is likely to be the most important factor 
determining risk for developing a CRE infection. In a 4-year case-control 
study (N=102), the only covariate independently associated with CRE 
in multivariate analysis was the cumulative number of prior antibiotic 
exposures: ORs (95% CI) were 1.43 (1.19 - 1.72), 2.05 (1.70 - 2.47) and 2.93 
(2.43 - 3.53) for 1, 2 and ≥3 antibiotic exposures, respectively.11 
It also appears that not only is prior cumulative antibiotic exposure 
a risk factor, but that the risk increases with increasing duration of 
treatment. Kritsotakis et al. demonstrated that this was the case for 
β-lactam/β-lactamase inhibitor combinations (OR 1.15 increase in 
resistance per day of use; p=0.001) and also for the fluoroquinolones, 
where increased duration of treatment amplified the effect of 
exposure to carbapenems (OR 1.02 for interaction term, p=0.0009).9
Suboptimal dosing may also be a contributing factor for the 
development of resistance, and as a consequence it is advisable that 
administration of those agents that are still left for treatment, such as 
colistin, should be optimised in terms of dose and by avoiding use of 
these agents on their own.12-14
 Recognising the extent to which antibiotics are inappropriately 
used in South Africa, the Federation of Infectious Diseases of 
Southern Africa (FIDSSA) recently hosted the 1st South African 
Antibiotic Stewardship Program (SAASP) in Johannesburg. While 
ASPs were initiated at pilot hospitals in South Africa, outpatient 
antibiotic use in this country has not been addressed and it is now 
crucial also to target general practitioners and the South African 
public as a whole. However, experience elsewhere suggests that it is 
not possible to influence antibiotic prescribers without instituting 
restrictive or even what may be perceived as punitive measures. How 
this will be implemented in South Africa remains unclear. 
Management of invasive devices 
CRE have been identified from device-associated infections, 
particularly catheter-associated urinary tract infections. Limiting 
the use of invasive devices and using defined strategies that prevent 
their contamination and infection might be another important 
intervention to prevent occurrence and spread of CRE.3 These 
strategies should be urgently implemented in all our hospitals. 
Fig. 1. Emergence and spread of carbapenemase genes among 
Enterobacteriaceae in South Africa (KPC = Klebsiella pneumoniae 
carbapenemases; GES = Guiana extended-spectrum β-lactamases; 
NDM = New Delhi metallo-β-lactamases; OXA-48 = oxacillinase-type 
carbapenemases; VIM = Verona integron-encoded metallo-β-lactamases).
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Urinary catheters should only be used in those patients who have 
appropriate indications, should be removed as soon as possible, 
and should have sterile, closed drainage systems. Aseptic insertion 
and maintenance of all catheters, according to protocols laid out in 
catheter ‘bundles’, are essential and constitute best care. 
The Best Care … Always! (BCA) campaign was initiated in 2009 to 
support southern African healthcare organisations in implementing 
specific, internationally recognised, evidence-based interventions 
that enhance patient safety and constitute current best practice in 
hospital care.15 Early BCA results are encouraging and significant 
strides have been made since some of these bundles have been 
implemented in over 200 South African hospitals. For example, 
in 40 and 42 acute-care hospitals of two private hospital groups, a 
significant decrease in central line infections from 5.24 and 5.78 
per 1 000 catheter days to 1.34 (p<0.0001) and 1.27 (p<0.0001) line 
days, respectively, was recently confirmed over an 18-month period 
(unpublished, A J Brink, February 2012). 
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